Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Has potential in cardiovascular and metabolic diseases

- PMLiVE

SMC approves Yescarta and Keytruda, rejects Perjeta

Cancer drugs lead the latest round of recommendations

Lucid Group tough it out with a weekend full of charity challenges

This weekend the Lucid charity working group, Lucid SPIRIT, took on two separate challenges to help raise funds for the Wycombe Homeless Connection and Children in Need.On Saturday seventeen Lucidians...

Lucid Group Communications Limited

- PMLiVE

Sarepta bounces back with new gene therapy data

Announces positive results in treatment of limb-girdle muscular dystrophy

- PMLiVE

UK immunology biotech MiroBio launches with $34m fundraising

Will develop therapeutic antibodies for autoimmune diseases

- PMLiVE

How technology is driving new trends in patient engagement

by Alicia Staley

- PMLiVE

Gilead builds case for Descovy PrEP after FDA approval

Reported statistically significant improvements in kidney function

- PMLiVE

J&J pledges $500m investment into HIV and tuberculosis R&D

Aims to help eliminate both diseases by 2030

- PMLiVE

Understanding the patient journey

What we can learn from customer service

- PMLiVE

J&J bags FDA breakthrough designation for prostate cancer drug

Could challenge rival PARP inhibitor Lynparza

- PMLiVE

Aspen to pay millions to NHS following drug pricing investigation

CMA found company colluded to create a monopoly in UK market

- PMLiVE

Gilead claims FDA okay for Descovy as second PrEP option

Can now push new indication before generics dent franchise

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links